Venus Medtech (Hangzhou) Inc. announced unaudited consolidated earnings results or the six months ended June 30, 2020. For the year, revenue was RMB 102,049,000 against RMB 107,423,000 a year ago. Loss for the period was RMB 43,538,000 against RMB 185,782,000 a year ago. Basic and diluted loss per share attributable to ordinary equity holders of the parent was RMB 0.11 against RMB 0.62 a year ago.